Delving into the Latest Updates on N-acetyl-D-mannosamine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-Actamido-2-deoxy-D-mannose, D-ManNAc, LB-301 - Leadiant Biosciences

+ [7]

Target-

Mechanism

Glycosylation stimulants, Proteins modulators

Therapeutic Areas

Nervous System DiseasesCongenital DisordersSkin and Musculoskeletal Diseases+ [2]

Active Indication

Distal MyopathiesGlomerulosclerosis, Focal SegmentalDistal Myopathy, Nonaka Type

Inactive Indication-

Originator Organization

National Institutes of Health

Active Organization

National Institutes of Health

National Human Genome Research Institute

Leadiant Biosciences, Inc.

Inactive Organization

National Institute of Diabetes & Digestive & Kidney Diseases

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC8H15NO6

InChIKeyMBLBDJOUHNCFQT-WCTZXXKLSA-N

CAS Registry3615-17-6

Background:
Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed.
Objective:
To test a study drug (ManNAc) in people with FSGS.
Eligibility:
People aged 18 years and older with FSGS.
Design:
Participants will have 6 to 7 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights.
ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home.
During clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms.
During overnight visits, participants will also have 24-hour urine collection.
A study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit.
Participants may meet with a dietitian to discuss nutrition while taking the ManNAc.
Participants may choose to have genetic tests.

Start Date11 Nov 2024

Sponsor / Collaborator

National Human Genome Research Institute

ACTRN12623000609651 / RecruitingNot ApplicableIIT

An open-label, randomised, three-arm crossover study to examine the comparative pharmacokinetics of ManNAc administered as an oral solution and as two novel oral tablet formulations in healthy adult males

Start Date13 Jul 2023

Sponsor / Collaborator

University of South Australia

ACTRN12622000394741 / CompletedNot ApplicableIIT

An open-label, randomised, two-arm crossover study to determine the absolute oral bioavailability of ManNAc in healthy adult males

Start Date17 Nov 2022

Sponsor / Collaborator

University of South Australia

100 Clinical Results associated with N-acetyl-D-mannosamine

Login to view more data

100 Translational Medicine associated with N-acetyl-D-mannosamine

Login to view more data

100 Patents (Medical) associated with N-acetyl-D-mannosamine

Login to view more data

159

Literatures (Medical) associated with N-acetyl-D-mannosamine

31 Dec 2024·Gut microbes

Integrative analysis with microbial modelling and machine learning uncovers potential alleviators for ulcerative colitis

Article

Author: Chen, Wei ; Zhu, Jinlin ; Lu, Wenwei ; Zhang, Hao ; Hu, Mingyi ; Chen, Jing ; Yin, Jialin ; Wang, Hongchao

Ulcerative colitis (UC) is a challenging form of inflammatory bowel disease, and its etiology is intricately linked to disturbances in the gut microbiome. To identify the potential alleviators of UC, we employed an integrative analysis combining microbial community modeling with advanced machine learning techniques. Using metagenomics data sourced from the Integrated Human Microbiome Project, we constructed individualized microbiome community models for each participant. Our analysis highlighted a significant decline in both α and β-diversity of strain-level microbial populations in UC subjects compared to controls. Distinct differences were also observed in the predicted fecal metabolite profiles and strain-to-metabolite contributions between the two groups. Using tree-based machine learning models, we successfully identified specific microbial strains and their associated metabolites as potential alleviators of UC. Notably, our experimental validation using a dextran sulfate sodium-induced UC mouse model demonstrated that the administration of Parabacteroides merdae ATCC 43,184 and N-acetyl-D-mannosamine provided notable relief from colitis symptoms. In summary, our study underscores the potential of an integrative approach to identify novel therapeutic avenues for UC, paving the way for future targeted interventions.

04 Sep 2024·RSC Advances

Soft X-ray spectromicroscopy of human fibroblasts with impaired sialin function.

Article

Author: Miinalainen, Ilkka ; Darin, Niklas ; Kangas, Salla M ; Uusimaa, Johanna ; Patanen, Minna ; Angervaniva, Pia ; Blomqvist, Maria ; Huttula, Marko ; Hinttala, Reetta ; Mansikkala, Tuomas

Salla disease (SD) is a lysosomal storage disease where free sialic acid (SA) accumulates in lysosomes due to the impaired function of a membrane protein, sialin. Synchrotron radiation-based scanning transmission soft X-ray spectromicroscopy (STXM) was used to analyze both SD patients' fibroblasts and normal human dermal fibroblasts (NHDF) from healthy controls. Both cell lines were also cultured with N-acetyl-d-mannosamine monohydrate (ManNAc) to see if it increased SA concentration in the cells. The STXM technique was chosen to simultaneously observe the morphological and chemical changes in cells. It was observed that free SA did not remain in the lysosomes during the sample processing, leaving empty vacuoles to the fibroblasts. The total cytosol and entire cell spectra, however, showed systematic differences between the SD and NHDF samples, indicating changes in the relative macromolecular concentrations of the cells. The NHDF cell lines contained a higher relative protein concentration compared to the SD cell lines, and the addition of ManNAc increased the relative protein concentration in both cell lines. In this study, two sample preparation methods were compared, resin-embedded thin sections and cells grown directly on sample analysis grids. While the samples grown on the grids exhibited clean, well-resolved spectra not masked by embedding resin, the low penetration depth of soft X-rays hindered the analysis to only the thin region of the microfilaments away from the thick nucleus.

01 Aug 2024·Clinical Pharmacology in Drug Development

Impact of Food on the Oral Absorption of N‐Acetyl‐D‐Mannosamine in Healthy Men and Women

Article

Author: Gahl, William A. ; Meola, Tahlia R. ; Fornasini, Gianfranco ; Reuter, Stephanie E. ; Evans, Allan M. ; Polasek, Thomas M. ; Huizing, Marjan

Abstract:

N‐Acetyl‐D‐mannosamine (ManNAc) is an endogenous monosaccharide and precursor of N‐acetylneuraminic acid (Neu5Ac), a critical sialic acid. ManNAc is currently under clinical development to treat GNE myopathy, a rare muscle‐wasting disease. In this randomized, open‐label, 2‐sequence, crossover study, 16 healthy women and men were administered a single oral dose of ManNAc under fasting and fed conditions. Blood samples were collected for 48 hours after dosing for quantification of plasma ManNAc and Neu5Ac concentrations. Noncompartmental pharmacokinetic and deconvolution analyses were performed using baseline‐corrected plasma concentration data. Administration of ManNAc in the fed state resulted in a 1.6‐fold increase in ManNAc exposure, compared to fasting conditions. A concurrent increase in Neu5Ac exposure was observed in the presence of food. Deconvolution analysis indicated that the findings were attributed to prolonged absorption rather than an enhanced rate of absorption. The impact of food on ManNAc pharmacokinetics was greater in women than men (fed/fasted area under the concentration‐time curve from time 0 to infinity mean ratio: 198% compared to 121%). It is hypothesized that the presence of food slows gastric emptying, allowing a gradual release of ManNAc into the small intestine, translating into improved ManNAc absorption. The results suggest that taking ManNAc with food may enhance its therapeutic activity and/or reduce the daily dosage requirement.

1

News (Medical) associated with N-acetyl-D-mannosamine

27 Apr 2021

·www.biospace.com

LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the signing of a research collaboration and exclusive option agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo). Under the terms of the agreement, the companies will collaborate on the development of treatments for two undisclosed indications based on GeneRide™, LogicBio's proprietary gene insertion platform. The agreement also grants Daiichi Sankyo an option to negotiate and acquire worldwide licenses for LogicBio's development programs in these two indications. Financial terms of the collaboration are not disclosed. "I am very pleased to announce this collaboration as a new milestone in the validation of our GeneRide platform. In 2020, we cleared our first Investigational New Drug (IND) application for GeneRide for the treatment of pediatric methylmalonic acidemia (MMA) patients and initiated the Phase 1/2 SUNRISE clinical trial. We also formed our first research agreement with another major pharmaceutical company to develop a drug candidate for Crigler-Najjar syndrome," said Frederic Chereau, president and chief executive officer of LogicBio. "By partnering with Daiichi Sankyo, a global leader in developing innovative medicines, we are reinforcing our commitment to bring innovative therapeutics to people living with serious genetic conditions including many that can present symptoms as early as infancy." The GeneRide platform harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. GeneRide supports the development of a new generation of genetic medicine able to insert a DNA segment into the human genome while potentially avoiding certain risks associated with other gene editing technologies. The therapy uses a viral vector to deliver the therapeutic gene, known as a transgene, to the nuclei of a patient's cells via one-time infusion. LogicBio's two lead development programs based on the GeneRide platform are focused on rare pediatric conditions. The company is currently evaluating LB-001 in the Phase 1/2 SUNRISE trial in MMA and LB-301 in Crigler-Najjar syndrome through another research collaboration. LogicBio is also advancing the development of sAAVyTM, its next-generation AAV capsid platform, designed to overcome limitations with the current generation of AAV-based gene therapies. About LogicBio Therapeutics, Inc. LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVyTM capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit . Bill Berry Berry & Company Public Relations W: 212-253-8881 C: 917-846-3862 bberry@berrypr.com Jenna Urban Berry & Company Public Relations W: 212-253-8881 C: 203-218-9180 jurban@berrypr.com Company Codes: NASDAQ-NMS:LOGC

Collaborate

100 Deals associated with N-acetyl-D-mannosamine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12536

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Distal Myopathies	Phase 3	-	National Institutes of Health	-
Distal Myopathies	Phase 3	-	Leadiant Biosciences, Inc.	-
Glomerulosclerosis, Focal Segmental	Phase 2	US	National Human Genome Research Institute	11 Nov 2024
Distal Myopathy, Nonaka Type	Phase 2	US	National Human Genome Research Institute	05 Feb 2015
Kidney Diseases	Phase 1	US	National Institute of Diabetes & Digestive & Kidney Diseases	07 Jul 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02346461 (Pubmed \| Genet Med) Manual	Phase 2	Distal Myopathy, Nonaka Type	12	ManNAc	edacwxsxgu(ibxdahxoxf) = upffgsnrjv azrsdbcvky (jyqbetngkg )	Positive	01 Nov 2021
NCT02639260 (Phase 1 Study of N-Acetylmannosamine (ManNAc) for Glomerular Disease, ASN2020)	Phase 1	Glomerular disease	7	ManNAc 3g single dose	tgluqmcfkg(veslnvqrfs) = There were no serious adverse events. Most subjects (5 of 6) that received ManNAc twice daily showed a marked reduction in urine PCR (26-54%), which correlated with the degree of glomerular hyposialylation sbqhubvomy (zfdiiktqiv ) View more	Positive	19 Oct 2020
NCT02346461 (CTgov)	Phase 2	Distal Myopathy, Nonaka Type	12	ManNAc (ManNAc: Cohort A)	ltgbhpeyyk(ctqudvndhn) = mqhjgkmvkh sxrgifndlo (engvzfcxag, dljrodsopm - yyfzolghds) View more	-	16 Apr 2019
NCT02346461 (CTgov)	Phase 2	Distal Myopathy, Nonaka Type	12	ManNAc (ManNAc: Cohort B)	ltgbhpeyyk(ctqudvndhn) = qjgbbwxwaa sxrgifndlo (engvzfcxag, pxilklqrkm - sjabhvfmrh) View more	-	16 Apr 2019
ASN2010	Not Applicable	Nephrosis, Lipoid Angptl4 \| NPHS2-Angptl4 \| PAN	-	ManNAc	arahbqbles(qhbsoeizca) = puvfhzseiz qvkrqgwext (zefidvtken )	Positive	16 Nov 2010